/PRNewswire/ Prapela, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to explore the use of its.
FDA clearance would make Prapela's product the first available medical device to treat newborns diagnosed with neonatal opioid withdrawal syndrome, the company said.
Prapela's promising treatment for opioid-exposed babies submitted to FDA apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.